1-Piperonylpiperazine

1-Piperonylpiperazine (MDBP) is metabolized by demethylenation and subsequent methylation to N- (4-hydroxy-3-methoxybenzyl) piperazine followedby partial glucuronidation or sulfation. 1-Piperonylpiperazine can alter the disposition and metabolism of 3,4-methylenedioxymethamphetamine (MDMA) in the brain and in peripheral organs. 1-Piperonylpiperazine can inhibit the MDMA-induced neurotoxicity[1].

32231-06-4

MDBP

12352005

H315, H319, H335

Biochemical Assay Reagents

Others

Neurological Disease

99.56

DMSO : 100 mg/mL (ultrasonic)

C1(CN2CCNCC2)=CC3=C(OCO3)C=C1

C12H16N2O2

220.27

H315, H319, H335

[1]Staack, R. F., & Maurer, H. H. (2004) . New designer drug 1- (3,4-methylenedioxybenzyl) piperazine (MDBP) : studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. Journal of mass spectrometry : JMS, 39 (3), 255–261.

Room Temperature

-20°C, 3 years; 4°C, 2 years (Powder)

http://file.medchemexpress.com/batch_PDF/HY-W012426/1-Piperonylpiperazine-SDS-MedChemExpress.pdf

Reference compound2

No Development Reported